Moderna and Merck's intismeran cuts melanoma recurrence 49% in Phase 3 INTerpath-001
核心洞察
Moderna and Merck (搜索)'s personalized mRNA cancer therapy intismeran reduced recurrence or death by 49% versus Keytruda alone in high-risk melanoma (搜索), with a hazard ratio of 0.51 at five-year follow-up.
The Phase 3 INTerpath-001 study met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival in patients with surgically removed Stage IIB-IV melanoma (搜索).
Detailed data will be presented on October 24 at the ESMO Congress in a Presidential Symposium, following top-line results reported in August 2026 without numerical data.
Moderna and Merck (搜索)'s personalized mRNA cancer therapy intismeran autogene reduced the risk of recurrence or death by 49% compared with Merck's Keytruda alone in certain high-risk melanoma (搜索) patients, according to Phase 3 data from the INTerpath-001 study presented at the ESMO 2026 meeting and detailed in a mid-September 2026 trial report. The hazard ratio was 0.51 at five-year follow-up.
The trial enrolled patients with high-risk Stage IIB-IV melanoma (搜索) whose tumors had been surgically removed. INTerpath-001 met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival. When the companies first reported top-line results in August 2026, they did not disclose numerical data, stating only that the improvements were statistically significant and clinically meaningful.
ESMO Presidential Symposium to Deliver Full Dataset
Detailed results from INTerpath-001 are scheduled for presentation on October 24 at the European Society for Medical Oncology Congress in a Presidential Symposium, a session reserved for clinical research the society considers cutting-edge and potentially practice-changing. The presentation is expected to provide the full dataset beyond the top-line results reported in August.
Attention now turns to what the complete data reveal about the magnitude and durability of the treatment benefit, and whether the melanoma (搜索) result can support the broader oncology opportunity for the personalized mRNA approach.
Expansion Across Solid Tumors
Moderna and Merck (搜索) are advancing intismeran across nine Phase 2 and Phase 3 studies spanning multiple tumor types, including non-small cell lung cancer (搜索), bladder cancer (搜索) and renal cell carcinoma (搜索). The goal is to determine whether the approach that showed promise in melanoma (搜索) can be replicated across different tumor types.
Moderna has described oncology as a potential major long-term value driver, with intismeran positioned as a key part of that opportunity. The broader oncology pipeline extends beyond intismeran, with the company developing separate mRNA-based cancer antigen therapies, a T-cell engager and a cell-therapy enhancer.
Financial Context
Moderna's most recent quarterly results, for the period ended July 31, 2026, showed revenue of USD 145.0 million, up 2.1% from the same quarter a year earlier, with earnings per share of minus USD 1.97, beating the consensus forecast of minus USD 2.03 by USD 0.06. The company posted a negative net margin of 141.43% and a negative return on equity of 28.30% in that quarter.
The next earnings release, covering the quarter ending September 2026, is expected on November 5, 2026, with a consensus estimate of minus USD 1.36 per share. Analysts forecast a full-year 2026 loss of USD 6.09 per share, even as revenue guidance suggests up to about 10% year-on-year growth from a roughly USD 3.5 billion 2025 base.